#USA #New York #Pomerantz #SEC Investigation #ADC Therapeutics

Pomerantz Law Firm Investigates ADC Therapeutics

Pomerantz LLP, a well-respected law firm recognized for its expertise in corporate, securities, and antitrust class litigation, recently announced that it is investigating claims on behalf of investors in ADC Therapeutics SA, which trades on the New York Stock Exchange under the ticker ADCT. This investigation comes in response to concerns regarding the company's latest press release and the implications it has for the financial wellbeing of its investors.

On December 3, 2025, ADC Therapeutics released significant data from the LOTIS-7 Phase 1b open-label clinical trial. This trial primarily evaluated the safety and efficacy of ZYNLONTA®, used in combination with the bispecific antibody, glofitamab (COLUMVI®), in patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the company framed the data positively, it also disclosed that adverse events were noted in two patients, one of which was potentially related to treatment. More alarmingly, ADC reported that cytokine release syndrome was observed in 36.7% of patients across various dose levels.

Following the release of this data, ADC Therapeutics’ share price witnessed a notable decline of 14.13%, dropping $0.65 to close at $3.95 per share on the same day. Such a stark drop raises critical questions about the disclosed information’s impact on investor confidence and whether the company's communication adhered to proper disclosure regulations set forth by the SEC.

In light of these developments, Pomerantz is calling on investors who experienced losses to step forward. The firm's attorney, Danielle Peyton, is leading the investigation, and she urges affected investors to reach out for further information regarding their rights and potential legal recourse. Investors can contact her directly at [email protected] or through the firm's dedicated line at 646-581-9980, ext. 7980.

The core of the investigation revolves around whether ADC Therapeutics, as well as its officers and directors, may have engaged in securities fraud or other unlawful business practices. Given the gravity of the situation and the potential ramifications for investors, it is critical to understand exactly how this situation unfolded. The financial implications of improper disclosures not only affect the company's valuation but also the livelihoods of its shareholders.

Pomerantz LLP has a storied history of standing up for the rights of investors and has been pivotal in securing millions in damages on behalf of its clients. The firm, established over 85 years ago by Abraham L. Pomerantz, is well-regarded for its efforts in fighting against corporate misconduct and is seen as a leader in securities class action lawsuits. This ongoing investigation into ADC Therapeutics may follow this established path as the firm advocates for those who believe they have been wronged by the company’s actions.

As ADC Therapeutics continues to navigate this challenging landscape, the firm’s handling of this situation will be closely watched, both by regulatory bodies and investors alike. The outcome may have broader implications for how biopharmaceutical companies disclose trial data, particularly when adverse effects are reported. The scrutiny that companies face when dealing with sensitive information is increasing, and ADC’s case could serve as a pivotal example for the industry.

Conclusion

Investors in ADC Therapeutics SA are encouraged to stay informed about this investigation as it develops. Pomerantz intends to uncover the truth behind these potential violations and protect the interests of those who may have invested in the company based on possibly misleading or incomplete information. As this case progresses, updates will be provided to ensure all stakeholders are aware of their legal rights and options.

For more information on this investigation or details about how to join the class action, potential claimants can visit Pomerantz's official website. The diligent efforts of law firms like Pomerantz highlight the crucial role of legal advocacy in protecting investor rights in the complex world of securities trading.